Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells 487 shares under 10b5-1 plan

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief Commercial Officer, MRD, Susan Bobulsky reported an open-market sale of 487 shares of common stock at $22.00 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, and she continues to hold 406,288 shares directly after the sale.

Insights

Equity compensation and insider-trading analyst

Pre-planned, very small insider sale relative to remaining holdings.

Chief Commercial Officer Susan Bobulsky completed an open-market sale of 487 Adaptive Biotechnologies common shares at $22.00 per share. The filing shows she still directly owns 406,288 shares after this transaction, indicating she retains a substantial equity position.

The footnote states the sale was made under a Rule 10b5-1 trading plan adopted on December 16, 2025. Such plans are set up in advance, so the timing of this trade is more consistent with routine portfolio or liquidity management than a discretionary market-timing decision.

There are no derivative exercises or tax-withholding events disclosed in this filing, and the derivative position table is empty. Subsequent company filings may provide additional context if further trades occur under the same 10b5-1 plan.

Insider Trade Summary 10b5-1

Net Seller: 487 shares ($10,714)

Net Sell 1 txn

Insider BOBULSKY SUSAN

Role Chief Commercial Officer, MRD

Sold 487 shs ($11K)

Type	Security	Shares	Price	Value
Sale	Common Stock	487	$22.00	$11K

Holdings After Transaction: Common Stock — 406,288 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 487 shares Sale price: $22.00 per share Post-transaction holdings: 406,288 shares +2 more

5 metrics

Shares sold 487 shares Open-market sale on 2026-07-01

Sale price $22.00 per share Price for common stock sold

Post-transaction holdings 406,288 shares Direct ownership after sale

Approximate transaction value $10,714 487 shares × $22.00 per share

Trading plan adoption date December 16, 2025 Rule 10b5-1 plan for this sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/06/2026 - 07:16 PM Accepted by SEC EDGAR 07/06/2026 - 07:15 PM Learn about SEC filing dates

FAQ

What insider transaction did Adaptive Biotechnologies (ADPT) report for Susan Bobulsky?

Adaptive Biotechnologies reported that Chief Commercial Officer, MRD, Susan Bobulsky sold 487 common shares in an open-market transaction at $22.00 per share. After this sale, she directly holds 406,288 shares, indicating she retained the vast majority of her reported equity position.

Was the ADPT insider sale by Susan Bobulsky made under a Rule 10b5-1 plan?

Yes. The filing states the sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on December 16, 2025. These pre-arranged plans schedule trades in advance, which generally makes the timing look more routine than discretionary market-timing activity.

How many Adaptive Biotechnologies shares does Susan Bobulsky own after the reported sale?

Following the reported transaction, Susan Bobulsky directly owns 406,288 shares of Adaptive Biotechnologies common stock. This figure comes from the Form 4’s post-transaction holdings column and shows that the 487-share sale affected only a small fraction of her reported stake.

What price did Susan Bobulsky receive per share in the ADPT stock sale?

The filing reports that Susan Bobulsky’s open-market sale was executed at a price of $22.00 per share. This per-share figure, multiplied by the 487 shares sold, implies gross transaction proceeds of approximately $10,714 before any related costs or taxes.

Does the ADPT Form 4 show any option exercises or derivative transactions for Susan Bobulsky?

No derivative transactions are shown in this Form 4. The transaction list includes only the sale of 487 shares of common stock, and the derivativeSummary section is empty, indicating no reported option exercises, conversions, or other derivative-related activities in this particular filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBULSKY SUSAN

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer, MRD

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S(1)		487	D	$22	406,288	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.

	Susan Bobulsky by Kyle Piskel, Attorney-in-Fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)